Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 16.09 Million CNY | -4.85% |
| 2022 | 16.91 Million CNY | 2.78% |
| 2021 | 16.45 Million CNY | 11.81% |
| 2020 | 14.71 Million CNY | -17.74% |
| 2019 | 17.89 Million CNY | -17.09% |
| 2018 | 21.58 Million CNY | 16.43% |
| 2017 | 18.53 Million CNY | 5.18% |
| 2016 | 17.62 Million CNY | 22.65% |
| 2015 | 14.36 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 3.99 Million CNY | -9.67% |
| 2024 Q2 | 3.99 Million CNY | 0.0% |
| 2023 Q2 | 3.66 Million CNY | -5.47% |
| 2023 Q4 | 4.42 Million CNY | 7.15% |
| 2023 Q1 | 3.87 Million CNY | -7.75% |
| 2023 Q3 | 4.12 Million CNY | 12.58% |
| 2023 FY | 16.09 Million CNY | -4.85% |
| 2022 Q2 | 3.81 Million CNY | -0.75% |
| 2022 Q1 | 3.84 Million CNY | -17.18% |
| 2022 FY | 16.91 Million CNY | 2.78% |
| 2022 Q3 | 5.05 Million CNY | 32.57% |
| 2022 Q4 | 4.2 Million CNY | -16.83% |
| 2021 Q4 | 4.63 Million CNY | 9.1% |
| 2021 FY | 16.45 Million CNY | 11.81% |
| 2021 Q3 | 4.25 Million CNY | 4.57% |
| 2021 Q2 | 4.06 Million CNY | 16.2% |
| 2021 Q1 | 3.49 Million CNY | -27.92% |
| 2020 Q4 | 4.85 Million CNY | 3.23% |
| 2020 Q3 | 4.7 Million CNY | 29.0% |
| 2020 Q2 | 3.64 Million CNY | 140.28% |
| 2020 Q1 | 1.51 Million CNY | -67.79% |
| 2020 FY | 14.71 Million CNY | -17.74% |
| 2019 Q4 | 4.71 Million CNY | -0.42% |
| 2019 Q3 | 4.73 Million CNY | 0.68% |
| 2019 Q2 | 4.69 Million CNY | 25.18% |
| 2019 FY | 17.89 Million CNY | -17.09% |
| 2019 Q1 | 3.75 Million CNY | -33.27% |
| 2018 Q3 | 5.89 Million CNY | -1.32% |
| 2018 Q4 | 5.62 Million CNY | -4.66% |
| 2018 FY | 21.58 Million CNY | 16.43% |
| 2018 Q2 | 5.97 Million CNY | 46.56% |
| 2018 Q1 | 4.07 Million CNY | 0.0% |
| 2017 FY | 18.53 Million CNY | 5.18% |
| 2016 FY | 17.62 Million CNY | 22.65% |
| 2015 FY | 14.36 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | 90.389% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 99.753% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | 44.081% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | 95.924% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 145.201% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | 97.081% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 98.955% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | 96.585% |
| PuraPharm Corporation Limited | 216.62 Million HKD | 92.571% |
| SSY Group Limited | 3.48 Billion HKD | 99.539% |
| JBM (Healthcare) Limited | 319.41 Million HKD | 94.962% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | 97.406% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 99.963% |